Call: 1-202-476-5000

Find a Doctor
Email this page Email This Page
Print this page Print This Page

  Join Us On:
  Follow Children's on Facebook  Facebook
  Follow Children's on Twitter  Twitter
  Watch Children's on YouTube  YouTube

Holly Jane Meany, MD

The Center for Cancer and Blood Disorders


Solid Tumor Program

View CRI Profile for Holly Jane Meany
Specialties: Neuroblastoma , Germ Cell Tumors , Rhabdomyosarcoma

Board CertificationsAmerican Board of Pediatrics/Hematology-Oncology
National Provider Identifier1194810325

Service LocationsChildren's National Medical Center - Sheikh Zayed Campus for Advanced Children's Medicine
111 Michigan Avenue, NW
Washington, DC 20010
Map | Driving Directions

Phone: 202-476-5000

Holly Jane Meany, MD, is a pediatric oncologist at Children's National. She is a member of the Solid Tumor Program.

Dr. Meany's clinical research is focused on phase I clinical trials and pharmacology in the development of new agents for treating pediatric cancers.
TypeSchoolLocationDegreeField of StudyYears
Undergraduate Education The College of William & Mary Williamsburg, VABachelor of Science 1991 -1995
Medical School Ohio State University College of Medicine Columbus, OHDoctor of Medicine 1996 -2000
National & International Recognitions
Career Development AwardAmerican Society of Clinical Oncology2009
The Young Investigators Award American Society of Clinical Oncology2006
Janet M Glasgow Memorial AwardAmerican Medical Women’s Association

Affiliations and Memberships
TitleInstitutionCommittee / SectionYears
MemberAmerican Society of Hematology
MemberAmerican Society of Clinical Oncology
MemberChildren's Oncology Group
Journal Article, Meany, H.J., Warren, K.E., Fox, E., et al (2009), Pharmacokinetics of temozolomide administered in combination with O(6)-benzylguanine in children and adolescents with refractory solid tumors, Cancer Chemotherapy Pharmacology.

Journal Article, Finklestein, J.Z., Kelleher, J., Meany, H.J., Reaman, G., Sato, J., Seibel, N.L., Sondel, P., Sun, J. (2008), Phase 2 Trial of Recombinant Tumor Necrosis Factor-alpha in Combination With Dactinomycin in Children With Recurrent Wilms Tumor, Journal of Immunotherapy, 0.

Journal Article, Aikin, A., Balis, F.M., Fox, E., Meany, H.J., Murphy, R.F., Whitcomb, P., Widemann, B.C. (2008), Pediatric Phase I Trial Design Using a Pharmacodynamic Marker as the Primary Endpoint, Journal of Clinical Oncology.

Journal Article, Balis, F.M., Fox, E., McCully, C., Meany, H.J., Tucker, C. (2007), The Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite (OSI-420) After Intravenous Administration of Erlotinib in Non-human Primates , Cancer Chemotherapy and Pharmacology.

Journal Article, Gidvani, V.K., Meany, H.J., Minniti, C.P. (2007), Utility of PET Scan to Predict Relapse in Pediatric Patients with Hodgkin’s Disease, Pediatric Blood & Cancer, 48, 4, 399-402.

Journal Article, Meany, H.J., Fox, E., Hagey, A.E., (2006), In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines, Proceedings of the American Association for Cancer Research.

Journal Article, Chen, K., Crosby, M.G., Heritage, D.W., Jahn, J., Leitenberg, D., Meany, H., Meloni-Ehrig, A.M., Mowrey ,P.N., Scheerle, J., Seibel, N., Suchan, S., Tirado, C.A. (2005), Isolated del(14)(q21) in a Case of Precursor B-cell Acute Lymphoblastic Leukemia, Cancer Genetics and Cytogenetics, 161, 82-85.

For a more comprehensive list of publications for Holly Meany, MD view the National Library of Medicine’s PubMed online database

Feedback Form